Life-long management of atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy following alcohol septal ablation: A10-year follow-up case report
Abstract
Alcohol septal ablation (ASA) is an established septal reduction therapy for patients with drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). However, its impact on the long-term incidence of atrial fibrillation (AF) remains unclear. We report a case of a 68-year-old man with HOCM who underwent successful ASA with an improvement in heart failure (HF) symptoms. Four years later, recurrent AF developed, requiring catheter ablation twice. Subsequently, subarachnoid hemorrhage occurred during anticoagulation therapy. Because of the high thromboembolic and bleeding risks and unsuitable anatomy for percutaneous left atrial appendage (LAA) closure, surgical LAA occlusion was performed. This case highlights the importance of lifelong AF management following successful ASA.
Related
- Managing a mavacamten non-responder in obstructive hypertrophic cardiomyopathy: A case report
- Percutaneous endomyocardial ablation as a septal reduction strategy in symptomatic obstructive hypertrophic cardiomyopathy: A 20-year single-center observational experience.
- Hypertrophic obstructive cardiomyopathy complicated by severe midventricular obstruction treated with percutaneous transluminal septal myocardial ablation using simultaneous contrast imaging with left ventriculography and coronary angiography: a case report
- GLP-1 Receptor Agonist Use and Long-Term Outcomes in Hypertrophic Cardiomyopathy With Obstructive Sleep Apnea
- Recurrence Rates and Outcomes After First Detected Atrial Fibrillation Episode in a Contemporary Hypertrophic Cardiomyopathy Center
BibTeX
@article{akita2026lifelong,
title = {{Life-long management of atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy following alcohol septal ablation: A10-year follow-up case report}},
author = {Keitaro Akita and Yoshihisa Naruse and Makoto Sano and Masahiro Hirano and Yuichiro Maekawa},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.8114-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8114-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Life-long management of atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy following alcohol septal ablation: A10-year follow-up case report
AU - Keitaro Akita
AU - Yoshihisa Naruse
AU - Makoto Sano
AU - Masahiro Hirano
AU - Yuichiro Maekawa
PY - 2026
DA - 2026/09/08
JO - Internal Medicine
DO - 10.2169/internalmedicine.8114-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8114-26/_article
AB - Alcohol septal ablation (ASA) is an established septal reduction therapy for patients with drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). However, its impact on the long-term incidence of atrial fibrillation (AF) remains unclear. We report a case of a 68-year-old man with HOCM who underwent successful ASA with an improvement in heart failure (HF) symptoms. Four years later, recurrent AF developed, requiring catheter ablation twice. Subsequently, subarachnoid hemorrhage occurred during anticoagulation therapy. Because of the high thromboembolic and bleeding risks and unsuitable anatomy for percutaneous left atrial appendage (LAA) closure, surgical LAA occlusion was performed. This case highlights the importance of lifelong AF management following successful ASA.
SN - 1349-7235
SN - 0918-2918
ER -